featured
The Impact of New Systemic Therapies on Survival and Time on Hormonal Treatment in HR+/HER2− MBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Impact of New Systemic Therapies on Survival and Time on Hormonal Treatment in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Population-Based Study in British Columbia From 2003 To 2013
Cancer 2019 Nov 21;[EPub Ahead of Print], D Le, C Speers, L Thompson, L Gondara, A Nichol, C LohrischFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.